癌症治疗中的肠道微生物代谢产物
Gut microbial metabolites in cancer therapy.
作者信息
Song Panwei, Peng Zhi, Guo Xiaohuan
机构信息
Institute for Immunology, Tsinghua University, Beijing 100084, China; School of Basic Medical Sciences, Tsinghua University, Beijing 100084, China; Beijing Key Lab for Immunological Research on Chronic Diseases, Tsinghua University, Beijing 100084, China; State Key Laboratory of Molecular Oncology, Tsinghua University, Beijing 100084, China; SXMU-Tsinghua Collaborative Innovation Center for Frontier Medicine, Shanxi Medical University, Taiyuan, Shanxi Province 030001, China.
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
出版信息
Trends Endocrinol Metab. 2025 Jan;36(1):55-69. doi: 10.1016/j.tem.2024.06.016. Epub 2024 Jul 14.
The gut microbiota plays a crucial role in maintaining homeostasis and promoting health. A growing number of studies have indicated that gut microbiota can affect cancer development, prognosis, and treatment through their metabolites. By remodeling the tumor microenvironment and regulating tumor immunity, gut microbial metabolites significantly influence the efficacy of anticancer therapies, including chemo-, radio-, and immunotherapy. Several novel therapies that target gut microbial metabolites have shown great promise in cancer models. In this review, we summarize the current research status of gut microbial metabolites in cancer, aiming to provide new directions for future tumor therapy.
肠道微生物群在维持体内平衡和促进健康方面发挥着关键作用。越来越多的研究表明，肠道微生物群可通过其代谢产物影响癌症的发生、预后和治疗。肠道微生物代谢产物通过重塑肿瘤微环境和调节肿瘤免疫，显著影响包括化疗、放疗和免疫治疗在内的抗癌治疗效果。几种针对肠道微生物代谢产物的新型疗法在癌症模型中显示出巨大潜力。在这篇综述中，我们总结了肠道微生物代谢产物在癌症方面的当前研究现状，旨在为未来的肿瘤治疗提供新方向。
Zotero 插件